Sab Biotherapeutics Inc (SABS) Stock Price, Quote & News

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Flo...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 845 2813

Website: www.sab.bio

Address:

777 W 41st St., Miami Beach, United States

JTebow_CWS Apr. 30 at 4:08 PM

$SABS

0 · Reply

BillionerOfKing Apr. 30 at 2:05 PM

$SABS Current Stock Price: $3.56 Contracts to trade: $4.0 SABS May 15 2026 Call Entry: $0.20 Exit: $0.38 ROI: 94% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

JTebow_CWS Apr. 30 at 7:17 AM

$SABS Purpose of Emergent Biosolutions Founder Fuad El-Hibri. M&A process? https://en.wikipedia.org/wiki/Fuad_El-Hibri

1 · Reply

JTebow_CWS Apr. 30 at 3:11 AM

$SABS Emergent BioSolutions Will help guide.

0 · Reply

stockboyaisle1 Apr. 29 at 6:46 PM

$SABS FYI: Zacks price target as of today:

0 · Reply

stockboyaisle1 Apr. 29 at 12:22 PM

$SABS I just saw this from Emergent. Nothing from SAB. Some of us investors have been here a decade supporting and continuing to invest. I emailed them last week regarding their lack of not providing timely information on the three day conference as their press release stated the presentations would be released each day. I heard nothing back and today we learn of this from their contractor. Really poor investor relations on SAB. Sorry for complaining but this is BS. https://www.stocktitan.net/news/EBS/emergent-bio-solutions-secures-long-term-strategic-manufacturing-wnufw0fe946m.html

1 · Reply

DDiamond_Handz Apr. 27 at 3:25 PM

$SABS what in the sam hell is going on here

2 · Reply

JTebow_CWS Apr. 26 at 10:52 PM

$SABS Always enjoy these podcasts. https://podcasts.apple.com/us/podcast/growing-places/id1608036951?i=1000724720841

0 · Reply

JTebow_CWS Apr. 22 at 8:59 PM

$SABS Super responders seen early. hATG is superior to rATG. Fast tracked would be my hope for these kids.

1 · Reply

FinnessaurusFlex Apr. 22 at 3:31 PM

$SABS fellow longs, I am itching to get back in. Do we think the bottom is behind us and we have some serious excitement ahead at this point? I'm out of the loop a bit.

3 · Reply

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

Mar 19, 2026, 4:01 PM EDT - 6 weeks ago

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Mar 17, 2026, 10:46 PM EDT - 6 weeks ago

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Mar 17, 2026, 4:01 PM EDT - 6 weeks ago

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Mar 10, 2026, 7:31 AM EDT - 7 weeks ago

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Mar 9, 2026, 5:16 PM EDT - 7 weeks ago

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 3:00 PM EDT - 7 weeks ago

SAB Biotherapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 9:00 AM EST - 2 months ago

SAB BIO to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:40 AM EST - 2 months ago

SAB Biotherapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 10:30 AM EST - 2 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 15, 2026, 10:30 AM EST - 3 months ago

SAB Biotherapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 4 months ago

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

Jan 6, 2026, 8:00 AM EST - 4 months ago

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 4 months ago

First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

Dec 17, 2025, 8:00 AM EST - 4 months ago

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

Dec 8, 2025, 8:00 AM EST - 5 months ago

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Dec 2, 2025, 3:50 PM EST - 5 months ago

SAB Biotherapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 13, 2025, 5:00 PM EST - 6 months ago

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Nov 12, 2025, 10:00 AM EST - 6 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 2:45 PM EST - 6 months ago

SAB Biotherapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 4, 2025, 8:30 AM EST - 6 months ago

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Sep 19, 2025, 7:24 AM EDT - 8 months ago

SAB BIO Highlights Data in Multiple Presentations at EASD

Sep 3, 2025, 4:05 PM EDT - 8 months ago

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Aug 7, 2025, 7:30 AM EDT - 9 months ago

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Jul 21, 2025, 7:30 AM EDT - 10 months ago

SAB BIO Announces Oversubscribed $175 Million Private Placement

May 9, 2025, 9:00 AM EDT - 1 year ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

Mar 31, 2025, 7:32 AM EDT - 1 year ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Feb 12, 2025, 10:00 AM EST - 1 year ago

SAB Biotherapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 6, 2025, 2:00 PM EST - 1 year ago

SAB Biotherapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 3:40 PM EST - 1 year ago

Why Is SAB BIO Stock Trading Lower On Tuesday?

Jan 28, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 23, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Nov 6, 2024, 5:05 PM EST - 1 year ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Sep 13, 2024, 7:00 AM EDT - 1 year ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 4, 2024, 7:05 AM EDT - 1 year ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Aug 8, 2024, 5:51 PM EDT - 1 year ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 5, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Jul 31, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Appoints Lucy To as Chief Financial Officer

Jun 20, 2024, 7:20 AM EDT - 2 years ago

SAb Biotherapeutics Rebrands as SAB BIO

Jun 18, 2024, 1:10 PM EDT - 2 years ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

May 30, 2024, 4:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 21, 2024, 7:15 AM EDT - 2 years ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024, 5:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 6, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Apr 16, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 8, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 4, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Mar 29, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Mar 25, 2024, 10:15 AM EDT - 2 years ago

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

JTebow_CWS Apr. 30 at 4:08 PM

$SABS

0 · Reply

BillionerOfKing Apr. 30 at 2:05 PM

0 · Reply

JTebow_CWS Apr. 30 at 7:17 AM

$SABS Purpose of Emergent Biosolutions Founder Fuad El-Hibri. M&A process? https://en.wikipedia.org/wiki/Fuad_El-Hibri

1 · Reply

JTebow_CWS Apr. 30 at 3:11 AM

$SABS Emergent BioSolutions Will help guide.

0 · Reply

stockboyaisle1 Apr. 29 at 6:46 PM

$SABS FYI: Zacks price target as of today:

0 · Reply

stockboyaisle1 Apr. 29 at 12:22 PM

1 · Reply

DDiamond_Handz Apr. 27 at 3:25 PM

$SABS what in the sam hell is going on here

2 · Reply

JTebow_CWS Apr. 26 at 10:52 PM

$SABS Always enjoy these podcasts. https://podcasts.apple.com/us/podcast/growing-places/id1608036951?i=1000724720841

0 · Reply

JTebow_CWS Apr. 22 at 8:59 PM

$SABS Super responders seen early. hATG is superior to rATG. Fast tracked would be my hope for these kids.

1 · Reply

FinnessaurusFlex Apr. 22 at 3:31 PM

$SABS fellow longs, I am itching to get back in. Do we think the bottom is behind us and we have some serious excitement ahead at this point? I'm out of the loop a bit.

3 · Reply

JTebow_CWS Apr. 22 at 12:02 PM

$SABS

0 · Reply

BioRich Apr. 21 at 11:27 PM

$SLS Smoke and mirrors, carrot waver. Stick with REAL companies with REAL trials and REAL futures. $KYTX , $CADL $TGTX are locks. If you're not a Rope Hat, check it $SABS you'll thank me later. Follow/Subscribe for more perspective and suggestions. That's how we find these gems and learn. Let's make some (more) money. Cheers!

3 · Reply

stockboyaisle1 Apr. 21 at 4:59 PM

$SABS Anyone understand why the drop? News?

1 · Reply

JTebow_CWS Apr. 21 at 1:55 AM

$SABS Probably the best European Conference for getting the word out. I got to buy more shares.

1 · Reply

Merlintrader Apr. 18 at 3:29 PM

$IDYA and $SABS: two parallel biotech catalysts for next week, with precise conference timing, official event links, and why this window matters https://www.merlintrader.com/two-parallel-biotech-catalysts-april2026/

0 · Reply

BioRich Apr. 17 at 3:27 PM

$SLS Better off buying $KYTX, $CADL, $SABS or $TGTX. Playing Opex games on an over inflated hype Bio isn't investing, that's gambling. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

3 · Reply

JTebow_CWS Apr. 15 at 10:21 PM

$SABS LinkedIn post.

0 · Reply

JTebow_CWS Apr. 15 at 7:59 PM

$SABS Good things here.

0 · Reply

JTebow_CWS Apr. 15 at 5:53 PM

$SABS Yep.

0 · Reply

Ruff22 Apr. 14 at 1:45 PM

$SABS what just happened? +300k shares traded at the same time but several lots at the same price?

0 · Reply

DDiamond_Handz Apr. 13 at 3:33 PM

$SABS thats a cup and handle formation if i ever seen one, 10min chart

0 · Reply

JTebow_CWS Apr. 12 at 6:56 PM

$SABS Awesome video from Dr Michael Haller MD. https://sab-bio-phase1-t1d-data-expert-perspective-march-2026.open-exchange.net/replay

1 · Reply

Market Cap	190.56M
Revenue (ttm)	0.00
Net Income (ttm)	13.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	628,600
Avg Vol	616,662
Day's Range	N/A - N/A
Shares Out	50.95M
Stochastic %K	9%
Beta	0.60
Analysts	Strong Sell
Price Target	$9.89